FDA approves Dupixent for severe chronic hives in teens and adults failing antihistamines.

The FDA has approved Dupixent (dupilumab) for treating chronic spontaneous urticaria (CSU) in patients aged 12 and older who do not respond well to standard antihistamine treatments. This is the first new treatment for CSU in over a decade. Dupixent effectively reduces symptoms like itching and hives by targeting specific inflammatory pathways. About 300,000 people in the U.S. have CSU that is not well controlled by current treatments.